This study evaluates the retinal and vascular features in patients with macular degeneration under the effects of Bevacizumab intravitreal injections using optical coherence tomography and optical coherence tomography angiography.
Bevacizumab is a vascular endothelial growth factor antagonist represent an efficacy treatment for exudative age-related macular degeneration acting on vascular hyperpermeability. The optical coherence tomography and optical coherence tomography angiography represent novel and non-invasive diagnostic techniques that allow a detailed and quantitative analysis of retinal and vascular features. The study evaluates the changes in optical coherence tomography and optical coherence tomography angiography parameters at baseline and after three monthly injections of Bevacizumab in exudative AMD.
Study Type
OBSERVATIONAL
Enrollment
38
Three monthly intravitreal injections of bevacizumab (1.25 mg/0.05 mL)
University of Naples "Federico II"
Naples, Italy
Study of retinal structural features in exudative age-related macular degeneration after intravitreal injections of Bevacizumab
The effectiveness of Bevacizumab injections for treating exudative age-related macular degeneration using optical coherence tomography. The parameters analyzed by optical coherence tomography: Central Macular Thickness and Subfoveal Choroidal thickness (microns).
Time frame: three months
Study of retinal vascular features in exudative age-related macular degeneration after intravitreal injections of Bevacizumab
The effectiveness of Bevacizumab injections for treating exudative age-related macular degeneration using optical coherence tomography angiography. The parameters analyzed by optical coherence tomography angiography were: retinal and choriocapillaris vessel density (%).
Time frame: three months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.